Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Shelf Life of Ronapreve, Xevudy Extended to 30 Months in Japan
March 1, 2023
- Japan Panel Backs Approval of 1st Nasal Flu Vaccine
February 28, 2023
- Pfizer’s Omicron-Adapted Jab for Ages 5-11 in Line for Japan Approval
February 28, 2023
- Nipro Pharma Told to Improve Biz over Violations Spanning 42 Products, Faked Records
February 27, 2023
- Japan Approves Precedex for Pediatric Use, Expands Labels for Nubeqa, Rinvoq, and More
February 27, 2023
- PMDA Reviewing 16 APIs for Paradoxical Drug Reaction
February 27, 2023
- Komeito Poised to Call for Govt Support on Meiji Pharma’s Nacubactam
February 27, 2023
- Japan Panel OKs Plan to Offer 2 Boosters for Elderly in FY2023; Program to Start from May
February 24, 2023
- Alexion’s Danicopan, Pfizer’s Elranatamab and 2 More APIs Get Orphan Tag
February 24, 2023
- Nipro Pharma Likely to Face Business Improvement Order over Violations
February 24, 2023
- MHLW Panel Maintains Caution against Xocova Use in Women Who Might Be Pregnant
February 22, 2023
- MOF to Work with Industry to Boost Drug Discovery, Minister Says on Trade Deficit
February 22, 2023
- MHLW to Launch SaMD Working Group to Compile Opinions by Summer
February 22, 2023
- Consider Special Characteristics of Patches If Govt Is to Revise LLP Pricing Rules: LDP League
February 21, 2023
- LDP Project Team Hears Report on Expert Panel Debate; Chair Voices Difficulty around Political Intervention
February 21, 2023
- LDP’s Generic League Aiming to Finalize Proposal in April for Honebuto Policy
February 21, 2023
- Avigan Used Improperly for 429 Patients in Observational Study: MHLW
February 21, 2023
- AZ’s Evusheld Gets Label Update on Repeat Dosing
February 21, 2023
- MHLW to Launch Fact-Finding Study on COVID-19 Vaccine Reactions
February 20, 2023
- Lilly’s Ulcerative Colitis Med Up for MHLW Panel Review on March 3
February 20, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…